For fiscal year 2026, Fresenius maintained guidance for organic revenue growth of 4% to 7%, with the midpoint of 5.5% slightly below the consensus of 5.7%. The company expects constant currency ...

The German dialysis specialist said U.S. treatment volumes declined and reported a lower net profit due to restructuring ...

Fresenius Medical Care and Humacyte have amended their international rights agreement for Symvess, an acellular tissue engineered vessel. The revised deal realigns ex U.S. distribution rights, ...

May 5 (Reuters) - Fresenius Medical Care said on Tuesday its revenue fell 6% in the first quarter of 2026, weighed down by significant currency effects, mainly from the weak U.S. dollar, and recent ...

Fresenius Medical Care (XTRA:FME) is back in focus after Humacyte adjusted the ex U.S. distribution rights for Symvess, an acellular tissue engineered vessel, reshaping how the partners approach ...

Fresenius SE reported quarterly results that narrowly missed expectations as pricing pressure in China weighed on its ...

Fresenius Medical Care AG (FMS) on Tuesday reported net income of $138.1 million in its first quarter.

Fresenius Medical Care said on Tuesday its U.S. volumes continued ‌to shrink in the first quarter of 2026, sending the German dialysis provider's shares falling close to 6%. Legalcategory· April 7, ...

With the former leader of the company’s pharmaceutical branch now steering Fresenius overall, new CEO Michael Sen is being frank about the need for a “reset.” The move could give the German drugmaker ...

Humacyte (HUMA) announced on Friday that the company regained the exclusive rights to develop and commercialize its lead ...